LivaNova PLC (NASDAQ:LIVN) Shares Acquired by Squarepoint Ops LLC

Squarepoint Ops LLC lifted its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 74.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 111,449 shares of the company's stock after buying an additional 47,494 shares during the quarter. Squarepoint Ops LLC owned approximately 0.21% of LivaNova worth $5,161,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in LIVN. Russell Investments Group Ltd. increased its position in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after purchasing an additional 219 shares in the last quarter. Sterling Capital Management LLC increased its position in LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock worth $75,000 after purchasing an additional 1,441 shares in the last quarter. Vestcor Inc purchased a new stake in LivaNova during the 4th quarter worth about $204,000. Optimize Financial Inc purchased a new stake in LivaNova during the 4th quarter worth about $208,000. Finally, Corton Capital Inc. purchased a new stake in LivaNova during the 4th quarter worth about $214,000. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Stock Up 0.2%

NASDAQ LIVN traded up $0.09 on Friday, reaching $43.26. The company had a trading volume of 140,729 shares, compared to its average volume of 650,869. The firm has a 50-day moving average of $38.98 and a 200-day moving average of $44.41. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $61.94. The firm has a market capitalization of $2.36 billion, a PE ratio of 102.87 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Analyst Ratings Changes

LIVN has been the subject of several recent analyst reports. Robert W. Baird lifted their price target on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Stifel Nicolaus decreased their target price on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Wall Street Zen cut LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price for the company in a report on Tuesday, May 20th. Finally, Barclays decreased their target price on LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a report on Thursday, May 8th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $59.29.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.